Thus, IGF2BP2 was demonstrated to enhance MALAT1 stability through m6A modification promoting the protein expression of its downstream target ATG12, thereby facilitating NSCLC progression and reducing patient survival (Table 4). This evidence concerns the gene IGF2BP2 and non-small cell lung carcinoma.